FDA emergency authorization for convalescent plasma as a treatment for COVID-19 is now on hold, the New York Times reports. National Institutes of Health leaders, including Drs. Francis Collins, Anthony Fauci, and H. Clifford Lane, said data from the largest trial to date — encompassing over 35,000 infused patients — are insufficient to justify approval, according to the Times. The results suggested that plasma lowered mortality in hospitalized patients when given within 3 days of diagnosis, but whether treating patients that early is realistic remains to be seen. In addition, there was no placebo group. The trial has enrolled over 66,000 patients thus far.